Gilead Sciences (GILD) FCF Payout Ratio Growth (1y) (2016 - 2026)
Gilead Sciences (GILD) FCF Payout Ratio Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -59.92% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 65.46% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -41.69% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 31.57% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 19.88% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -41.72% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -78.31% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 498.33% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -78.31% |
| Mar 31, 2026 | -29.79% |
| Dec 31, 2025 | -7.56% |
| Sep 30, 2025 | 7.16% |
| Jun 30, 2025 | 69.20% |
| Mar 31, 2025 | 31.02% |
| Dec 31, 2024 | -28.71% |
| Sep 30, 2024 | -59.83% |
| Jun 30, 2024 | 88.65% |
| Mar 31, 2024 | -20.80% |
| Dec 31, 2023 | 24.08% |
| Sep 30, 2023 | 69.26% |
| Jun 30, 2023 | -22.78% |
| Mar 31, 2023 | 0.04% |
| Dec 31, 2022 | 33.09% |
| Sep 30, 2022 | 18.64% |
| Jun 30, 2022 | 36.68% |
| Mar 31, 2022 | 55.99% |
| Dec 31, 2021 | -40.35% |
| Sep 30, 2021 | -29.69% |